Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the treatment choice between targeted therapy and immunotherapy in a patient with an EGFR Mutation and high PDL-1.
Case Based Panel Discussion - Choosing Between Targeted Therapy and Immunotherapy in a Patient with an EGFR Mutation and High PDL-1 Expression
, , , ,
The Global Resource for Advancing Cancer Education (GRACE), in partnership with Georgetown University Hospital is pleased to present the videos from the panel discussion "2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know".
Dr. Vamsidhar Velcheti with the Cleveland Clinic joined GRACE to discuss updates to our Lung Cancer Video Library. In this video, Dr. Velcheti discusses MET as a target in advanced non-small cell lung cancer.
Lung Cancer Video Library 2017 - New Options in Acquired Resistance for ALK Positive Non-small Cell Lung Cancer (NSCLC)
Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses new options in acquired resistance for ALK positive non-small cell lung cancer (NSCLC).
Lung Cancer Video Library - Molecular Testing At Initial Diagnosis Of Advanced Non-Small Cell Lung Cancer (NSCLC) Current Standards
Stephen Liu, MD provides updates to our Lung Cancer Video Library. In this recent video, Dr. Liu discusses current standards for Molecular Testing At Initial Diagnosis Of Advanced Non-Small Cell Lung Cancer (NSCLC).
- 1 of 8
- View More
New FDA Approval for Zykadia (ceritinib) for ALK-Positive NSCLC: Why I Think It's a Poor Choice for Initial Treatment
The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The...
GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum, September 16, 2017. See more information about our presenters in Speaker Highlights - today we introduce James Stevenson, MD.
Imprecision Medicine: Why Keytruda (Pembrolizumab) + Chemo for PD-L1+ NSCLC isn't Ready for Prime Time
Let me start by saying that I'm a fan of the immune checkpoint inhibitor Keytruda (pembrolizumab) and consider it the new standard of care as a...
In this thirteenth video, the fifth from the afternoon breakout survivorship sessions, GRACE presents Exercise for Lung Cancer Patients, with Jeffrey Eagan DPT.
In this twelfth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The fourth video from these sessions is Dealing with Down Days, presented by Jeanice Hansen, MSW, LCSW, OSW-C.
- 1 of 123
- View More
No Result Found